Back to Search
Start Over
Update on infective complications in patients treated with alemtuzumab for multiple sclerosis: review and meta-analysis of real-world and randomized studies
- Source :
- Expert opinion on drug safety. 20(10)
- Publication Year :
- 2021
-
Abstract
- Objective: We aimed to systematically assess the pooled prevalence of infective complications in randomized controlled trials (RCTs) and real-world studies (RWSs) investigating alemtuzumab treatment in multiple sclerosis (MS), also looking at selected infections and their severity. Methods: We included in the analysis RCTs and RWSs investigating the use of alemtuzumab in MS in which infective complications were reported, as well as case reports of rare infections. We conducted a meta-analysis of proportions and a random effect model meta-regression to investigate heterogeneity. Results: The pooled prevalence of infective complications in alemtuzumab treated MS patients is 24%. The most common reported infections are respiratory tract infections (47%) and the most part of the infections are mild-to-moderate (85%). Severe infections account for 6% of the total estimate. We found first-time-reported cases of invasive aspergillosis, hepatitis E virus infection, EBV hepatitis, and cerebral toxoplasmosis. The prevalence of infections is higher in studies conducted before 2009, and in studies with higher proportion of male participants. Conclusions: Clinicians should be aware that the prevalence of serious infections during alemtuzumab can be higher than expected from RCTs. Peculiar opportunistic infections should be considered when evaluating a patient treated with alemtuzumab who develops signs of infection.
- Subjects :
- medicine.medical_specialty
Multiple Sclerosis
Immunologic Factors
opportunistic infection
Opportunistic Infections
Severity of Illness Index
law.invention
Immunologic Factor
Randomized controlled trial
law
Internal medicine
Severity of illness
medicine
Prevalence
Humans
Pharmacology (medical)
In patient
monoclonal antibodie
Alemtuzumab
Randomized Controlled Trials as Topic
business.industry
Multiple sclerosis
General Medicine
medicine.disease
multiple sclerosi
Meta-analysis
business
Human
medicine.drug
Subjects
Details
- ISSN :
- 1744764X
- Volume :
- 20
- Issue :
- 10
- Database :
- OpenAIRE
- Journal :
- Expert opinion on drug safety
- Accession number :
- edsair.doi.dedup.....4fb173d6bcfe3a8054cb2a0ec385995c